Conglomerate of Rheumatology and Spondylitis Organizations Released New Updated Guidelines Against Mandatory Switching to Biosimilars
- The new updated guidelines are being built on previous recommendations based on best practices for imaging- managing biologic and biosimilars usage in patients- and providing information on new medication
- The guidelines included 20 clinical questions based on pharmacological treatment indicated in 2015 guidelines and 26 new question on the pharmacological treatment treat-to-target strategy- and use of imaging in addition to separate voting panel and recommendations were labeled
- Additionally- the guidelines also included recommendation against mandatory switching to biosimilar as a first anti-TNF treatment in patients whose disease is still active as the biosimilar will have the same response as the original one
Click here to read full press release/ article | Ref: American College of Rhuematology | Image: Behance
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com